LCP
TEVA icon

LGT Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

LGT Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-287,710
Closed -$16.5M – 79
2014
Q4 		$16.5M Buy
287,710
+7,550
+3% +$421K 4.22% 5
2014
Q3 		$15.1M Buy
280,160
+17,330
+7% +$918K 3.89% 7
2014
Q2 		$13.8M Buy
+262,830
New +$13.4M 3.24% 5

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

LGT Capital Partners's TEVA Position: Q1 2015 in Review

LGT Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2015, closing a stake of 287,710 shares — an estimated $16.5M sold.

LGT Capital Partners first reported a position in TEVA in Q2 2014 and held it in 3 quarters. The position peaked at $16.5M in Q4 2014. 822 funds tracked by Wall St. Rank hold TEVA as of Q1 2015.

  • LGT Capital Partners reported no remaining Teva Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • LGT Capital Partners sold 287,710 Teva Pharmaceuticals shares in Q1 2015, an estimated $16.5M.
  • LGT Capital Partners first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • LGT Capital Partners's Teva Pharmaceuticals position peaked at $16.5M in Q4 2014.
  • 822 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2015.

Based on LGT Capital Partners's 13F filing for Q1 2015, filed 21 May 2015.